# STAAR Surgical (STAA): After a 9% Earnings Pop, a Contrarian Says the Turnaround Can Reach $50 > STAAR Surgical closed at $27.17 on November 4, 2026, up about 9% after third-quarter results. A contrarian investor who first recommended the stock near $17.50 after a rejected Alcon bid now calls the print more proof of a turnaround and says $50 is reachable. We check underlying sales, China, cash, Point72's disclosed stake and what would prove him wrong. By MCAFax · Published November 5, 2026 Section: Markets & Main Street › From Wall Street · Series: Market Calls, Investigated (https://mcafax.com/notebook/series/market-calls-investigated) Canonical: https://mcafax.com/notebook/staa-staar-surgical-post-earnings-turnaround-50-dollar-case Source: MCAFax, The Broker's Notebook (https://mcafax.com/notebook). MCAFax is not a lender or a law firm. --- STAAR Surgical (NASDAQ: STAA) closed at $27.17 on November 4, 2026, up about 9% after third-quarter results. Contrarian investor Z, who first recommended the stock near $17.50 after a rejected Alcon bid, says the print reinforces a turnaround and that $50 is reachable with patience. Skeptics still see a 12% year-over-year sales drop on the headline and gross margins stuck near 71%. *This is journalism and commentary, not investment advice. We hold no position unless stated.* ## Key facts - **Ticker:** STAA on Nasdaq; situation type is a post-bid turnaround in implantable lenses. - **The call:** Z [posted](https://x.com/ZeeContrarian1/status/2118315960331297033) on November 5 that "the turnaround continues" and that it is "not hard" for him to see $50; STAAR is now his second-largest position. - **Price:** $27.17 at the November 4 close, the last close before his post; about $1.5 billion market value by his math and our check. - **Q3 sales:** $83.4 million, down 12% year over year; up 21% excluding $25.9 million of deferred China sales recognized in Q3 2025, per the [company release](https://www.businesswire.com/news/home/20261104516093/en/STAAR-Surgical-Reports-Third-Quarter-2026-Results). - **Profit and cash:** net income $5.6 million ($0.11 diluted); adjusted EBITDA $14.4 million; cash and investments $206.4 million with no debt. - **Buyback:** board authorized a $50 million share repurchase program. - **China / EMEA:** China sales $39.3 million (up 31% ex-deferred); EMEA up 31% year over year. - **Next test:** whether gross margin recovers from 70.9% starting in the fourth quarter, as management said. ## Is STAA a good bet after the earnings pop? It depends on whether you believe underlying demand and the balance sheet matter more than the headline year-over-year sales drop. The stock has already risen about 30% over the past month and about 45% from recent lows on Z's telling, so the debate is about remaining upside, not a washed-out stub. ## Why are investors bullish on STAAR Surgical? - **Underlying growth.** Excluding the deferred China sales in the year-ago quarter, sales rose 21%, with China up 31% and EMEA up 31%. - **Cash and no debt.** $206.4 million of cash and investments and a debt-free balance sheet fund buybacks and product work. - **Buyback.** A new $50 million authorization signals the board thinks the shares are cheap relative to the franchise. - **Moat claim.** Z cites Collamer technology, regulatory history and surgeon relationships as reasons competitors struggle to catch up in implantable lenses. - **Prior bid context.** Alcon's proposed $30.75 takeout was blocked by Broadwood Partners; Z argues the business is "many times better" now than when that offer was rejected. ## Who's making this call and why? Z posts contrarian special-situation ideas. On November 5 he [wrote](https://x.com/ZeeContrarian1/status/2118315960331297033): "It's not hard for me to see $STAA reaching $50 per share with patience." He says he first recommended the stock near $17.50 and that it is now his second-largest holding after the rally. **Track record.** In our tracking he is 12-11 on 23 calls scored at 180 days against the S&P 500, with an average edge of +3.6 points. His long book went 6-9 in that sample. See the [scoreboard](https://mcafax.com/notebook/market-calls-scoreboard). **Other voices.** Stifel maintained a Buy and raised its price target to $34 from $31 after the print, according to market summaries circulating on X; that is a Street target, not a tracked north-star call. Point72 Asset Management filed a Schedule 13G in May 2026 showing a stake of about 5.2%. Z says Point72 bought near $29; we did not independently verify a fresh purchase immediately before the November print. ## Who disagrees? Headline readers stress the reported year-over-year declines. One earnings summary account [noted](https://x.com/AlfaFinderUSA/status/2118099578956501152) that operating income "plummeted" as revenue fell 12% to $83.4 million. Gross margin was 70.9%, versus 82.2% a year earlier (and about 75.5% excluding the deferred China sales effect, per the call). Management expects China seasonality to moderate near-term revenue and earnings even if free cash flow holds. Other risks: - **Factory limits.** Commentary around the print said Chinese demand for some lenses outran supply, capping volume. - **Already re-rated.** After a roughly 45% bounce from the lows Z cites, more of the turnaround may already be in the price. - **Prior coverage.** We featured a STAAR piece in mid-October after the Alcon fight; this is a new post-earnings check, not a new name. ## What are the key facts to verify? - The BusinessWire release for Q3 sales, the China deferral bridge, cash and the $50 million buyback. - Gross margin in Q4 and into 2027 versus the 70.9% print. - Point72's latest 13F or amendments versus the May 2026 Schedule 13G. - Any update on U.S. sales staying above $6 million a quarter. ## What would prove it right or wrong? Signals the turnaround thesis is working: - Underlying sales growth holding in the high teens or better with China volume catching supply. - Gross margin moving back toward the mid-70s as temporary costs fade. - Buybacks executed without starving product investment. Signals it is fading: - China growth stalling once supply catches up, or another gross-margin miss. - Cash falling as working capital or tariffs bite. - A failed repurchase or a capital raise that undercuts the debt-free story. *This is journalism and commentary, not investment advice. We hold no position unless stated.* ## Questions readers ask **Is STAAR Surgical (STAA) stock a good bet after the Q3 pop?** It depends on how much weight you give underlying growth versus the headline year-over-year sales drop. STAAR closed at $27.17 on November 4, 2026, up about 9% after reporting $83.4 million of sales. Sales were down 12% year over year but up 21% excluding $25.9 million of deferred China sales recognized in Q3 2025. Contrarian investor Z says the turnaround continues and that $50 is reachable. Gross margin was 70.9%, and management expects improvement starting in Q4. **What did STAAR Surgical report for the third quarter of 2026?** Net sales were $83.4 million, net income was $5.6 million or $0.11 per diluted share, and adjusted EBITDA was $14.4 million. Cash, cash equivalents and investments were $206.4 million with no debt. For the first nine months, sales were a record $270.5 million. **Why did STAAR's sales fall 12% year over year?** The year-ago quarter included $25.9 million of previously deferred China sales. Excluding that item, prior-year sales were $68.8 million and third-quarter 2026 sales rose 21% against that base, per the company. **What is happening in China for STAAR?** China sales were $39.3 million in the third quarter. That was down 30% including the deferred sales in the prior year, but up 31% excluding them. The company also said it finished moving Chinese-market ICL manufacturing to Switzerland to cut U.S.-China tariff exposure. **Did STAAR authorize a buyback?** Yes. The board authorized a $50 million share repurchase program, citing confidence in the business and a view that the shares are undervalued. **Who is Z and what is his STAAR call?** Z posts contrarian ideas on X as ZeeContrarian1. He says he first recommended STAAR near $17.50 after the rejected Alcon bid, that the stock is now his second-largest position, and that he can see $50 with patience. In our tracking he is 12-11 on 23 scored calls at 180 days versus the S&P 500. **What was the Alcon bid for STAAR?** Alcon proposed to buy STAAR at $30.75 a share. Broadwood Partners, a large holder, opposed the deal as too opportunistic, and the bid did not close. Z argues the business is stronger now than when that offer was made. **Does Point72 own STAAR?** Point72 Asset Management filed a Schedule 13G in May 2026 disclosing a stake of about 5.2%. Z says the firm bought near $29; we did not independently confirm a new purchase immediately before the November 2026 earnings. **What is STAAR's gross margin?** Third-quarter 2026 gross margin was 70.9%, compared with 82.2% a year earlier. Management said temporary pressures should ease beginning in the fourth quarter. **What would show the $50 case is working?** Sustained underlying sales growth, a gross-margin recovery from 70.9%, and buybacks that shrink the share count without starving growth. A China slowdown, another margin miss or a cash drain would undercut the case.